Siegel RL, Miller KD, Fuchs HE et al (2021) Cancer statistics, 2021. CA Cancer J Clin 71:7–33

Article  PubMed  Google Scholar 

Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30

Article  PubMed  Google Scholar 

Nagase S, Ohta T, Takahashi F et al (2022) Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology. Annual Patient Report for 2018 and Annual Treatment Report for 2013. J Obstet Res Gynaecol 48:541–552

Article  Google Scholar 

Morice P, Leary A, Creutzberg C et al (2016) Endometrial cancer. Lancet 387:1094–1108

Article  PubMed  Google Scholar 

Wada M, Yamagami W. (2024) Immunotherapy for endometrial cancer. Int J Clin Oncol Online ahead of print.

Cancer Genome Atlas Research Network, Kandoth C, Schultz N et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73

Article  Google Scholar 

Kommoss S, McConechy MK, Kommoss F et al (2018) Final validation of the promise molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 29:1180–1188

Article  CAS  PubMed  Google Scholar 

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570

Article  CAS  PubMed  Google Scholar 

Yaguchi T, Kawakami Y (2016) Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 28:393–309

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peng H, He X, Wang Q (2022) Immune checkpoint blockades in gynecological cancers: a review of clinical trials. Acta Obstet Gynecol Scand 101:941–951

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taube JM, Klein A, Brahmer JR et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064–5074

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Felice F, Marchetti C, Tombolini V et al (2019) Immune check-point in endometrial cancer. Int J Clin Oncol 24:910–916

Article  PubMed  Google Scholar 

Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856

Article  CAS  PubMed  Google Scholar 

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dudley JC, Lin MT, Le DT et al (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22:813–820

Article  CAS  PubMed  Google Scholar 

Mishima S, Taniguchi H, Akagi K et al (2020) Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology First Edition. Int J Clin Oncol 25:217–239

Article  CAS  PubMed  Google Scholar 

Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377:2500–2501

Article  PubMed  PubMed Central  Google Scholar 

Vanderwalde A, Spetzler D, Xiao N et al (2018) Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 7:746–756

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:1974–1982

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38:1–10

Article  CAS  PubMed  Google Scholar 

Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680

Article  CAS  PubMed  Google Scholar 

Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413

Article  CAS  PubMed  PubMed Central  Google Scholar 

NCCN (2024) NCCN clinical practice guidelines in oncology, Uterine Neoplasms version 3. Available via https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf Accessed Oct 2024

Taylor MH, Betts CB, Maloney L et al (2022) Safety and efficacy of pembrolizumab in combination with Acalabrutinib in advanced head and neck squamous cell carcinoma: phase 2 proof-of-concept study. Clin Cancer Res 28:903–914

Article  CAS  PubMed  Google Scholar 

Makker V, Colombo N, Casado Herráez A et al (2022) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. N Engl J Med 386:437–448

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makker V, Colombo N, Casado Herráez A et al (2023) Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775. Clin Oncol 41:2904–2910

CAS  Google Scholar 

Yonemori K, Yunokawa M, Ushijima K et al (2022) Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: results from Study 309/KEYNOTE-775. Cancer Sci 113:3489–3497

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oaknin A, Pothuri B, Gilbert L et al (2023) Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res 29:4564–4574

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mirza MR, Chase DM, Slomovitz BM et al (2023) Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 388:2145–2158

Article  CAS  PubMed  Google Scholar 

Mirza MR, Shahin MS, Powell MA et al (2023) Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial. J Clin Oncol 41:TSP5504

Article  Google Scholar 

Eskander RN, Sill MW, Beffa L et al (2023) Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 388:2159–2170

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westin SN, Moore K, Chon HS et al (2024) Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol 42:283–299

Article  CAS  PubMed  Google Scholar 

Colombo N, Harano K, Hudson E et al (2024) Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 25(9):1135–1146